

medicina

BUENOS AIRES Vol. 82 Supl. V - 2022



medicina

BUENOS AIRES, VOL. 82 Supl. V - 2022

COMITÉ DE REDACCIÓN

Sebastián F. Ameriso <i>FLENI, Buenos Aires, Argentina</i>	Basilio A. Kotsias <i>Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina</i>
Pablo J. Azurmendi <i>Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina</i>	Gustavo Kusminsky <i>Hospital Universitario Austral, Buenos Aires, Argentina</i>
Damasia Becú Villalobos <i>Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina</i>	Oscar M. O. Laudanno <i>Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina</i>
Gabriela V. Carro <i>Hospital Nacional Prof. A. Posadas, Buenos Aires, Argentina</i>	Isabel A. Lüthy <i>Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina</i>
José H. Casabé <i>Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina</i>	Jorge A. Manni <i>Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina</i>
Hugo N. Catalanó <i>Hospital Alemán, Buenos Aires, Argentina</i>	Domingo J. Palmero <i>Hospital de Infecciosas Dr. Francisco J. Muñiz, Instituto de Tisiopneumología Prof. Dr. Raúl Vacarezza, Facultad de Medicina, UBA, Argentina</i>
Eduardo L. De Vito <i>Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina</i>	Guillermo B. Semeniuk <i>Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina</i>
Laura I. Jufé <i>Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina</i>	Oswaldo J. Stringa <i>Hospital de Clínicas José de San Martín, UBA, Argentina</i>
Isabel Narvaiz Kantor <i>Organización Panamericana de la Salud (OPS/OMS), Argentina</i>	

MIEMBROS EMÉRITOS

Héctor O. Alonso <i>Instituto Cardiovascular Rosario, Santa Fe, Argentina</i>	Christiane Dosne Pasqualini <i>Academia Nacional de Medicina, Buenos Aires, Argentina</i>
María Marta de Elizalde de Bracco <i>IMEX-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina</i>	Rodolfo S. Martin <i>Facultad de Ciencias Biomédicas, Hospital Universitario Austral, Buenos Aires, Argentina</i>
Guillermo Jaim Etcheverry <i>Facultad de Medicina, UBA, Argentina</i>	
Daniel A. Manigot <i>Hospital San Juan de Dios, Buenos Aires, Argentina</i>	La Tapa Maternidad Transgénica, 2007 Chino Benítez

MEDICINA (Buenos Aires) - Revista bimestral – ISSN 1669-9106 (En línea)

Registro de la Propiedad Intelectual N° 02683675
Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires) Propietario de la publicación: Fundación Revista Medicina
Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.
MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.
Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.
Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.
Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Isabel Lüthy

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,
1427 Buenos Aires, Argentina
Tel. 5287-3827 Int. 73919 y 4523-6619
e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 82, Supl. V, Noviembre 2022

Diagramación y Diseño: Andrés Esteban Zapata - aez.sgi@gmail.com

REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022

**LXVII REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)**

**LXX REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI) &
3ER CONGRESO FRANCO-ARGENTINO DE INMUNOLOGÍA (FAIC)**

**REUNIÓN ANUAL 2022 DE LA
SOCIEDAD ARGENTINA DE FISIOLOGÍA (SAFIS)**

16-19 de noviembre de 2022
Hotel 13 de Julio – Mar del Plata

EDITORES RESPONSABLES

Dr. Daniel Alonso
Dr. Emilio Malchiodi
Dr. Martín Vila Petroff
Dra. Caroline Lamb

JOINT MEETING SAIC SAI&FAIC SAFIS 2022

**LXVII ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)**

**LXX ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI) & 3RD
FRENCH-ARGENTINE IMMUNOLOGY CONGRESS (FAIC)**

**ANNUAL MEETING 2022 OF
SOCIEDAD ARGENTINA DE FISIOLOGÍA (SAFIS)**

November 16-19, 2022
13 de Julio Hotel – Mar del Plata

RESPONSIBLE EDITORS

Dr. Daniel Alonso
Dr. Emilio Malchiodi
Dr. Martín Vila Petroff
Dr. Caroline Lamb

measuring the initial transport rate (ITR) of its fluorescent metabolite, GSH-S-methylfluorescein (GS-MF), a Mrp2 substrate. ITR, expressed as percent of C, was reduced by TLC (-25%), and this effect was prevented by MG132 (+6%). We conclude that sustained endocytosis of Mrp2 in cholestasis leads to its exacerbated proteosomal degradation. This finding could be relevant to understand the impairment of hepatocanalicular transporters in chronic cholestasis.

137. (524) ESTRADIOL 17 β -D-GLUCURONIDE-INDUCED NADPH OXIDASE IMPAIRS Mrp2 ACTIVITY BY CONTRIBUTING TO ITS CELLULAR INTERNALIZATION IN SANDWICH CULTURED RAT HEPATOCYTES

Gimena Salas, Alen A. Litta, Virginia S. Schuck, Anabela C. Medeot, Romina B. Andermatten, Cecilia L. Basiglio, Fernando A. Crocenzi¹.

¹Instituto de Fisiología Experimental (IFISE)

Estradiol 17 β -D-glucuronide (E17G) alters canalicular secretion via several kinase-mediated signaling pathways which induce endocytosis and intracellular retention of canalicular transporters, the MEK-ERK1/2 pathway contributing to the second process. Previously, we found that NADPH oxidase (NOX)-generated reactive oxygen species (ROS) are partly responsible for the impairment of canalicular Mrp2 transport activity induced by E17G, and that NOX shares the MEK-ERK1/2 signaling pathway, downstream these kinases. We aimed to evidence that E17G-induced NOX-mediated functional impairment of Mrp2 transport is dependent on its internalization. Intracellular distribution of Mrp2 was assessed by immunofluorescence and confocal microscopy analysis in sandwich cultured rat hepatocytes (SCRH). First, SCRH were treated with vehicle (DMSO, control), E17G (200 μ M, 20 min) or pre-treated with apocynin (Apo, NOX inhibitor, 100 μ M, 30 min) prior to E17G. Then, SCRH were fixed, permeabilized, and incubated with a specific antibody to Mrp2, and then with a secondary antibody and Alexa Fluor 568-conjugated phalloidin for F-actin staining, which is mainly pericanalicular (demarcating the canaliculi) and barely evident in the basolateral membrane. Mrp2 internalization was evaluated in confocal images (n=12 canaliculi, from 3 independent cultures) by calculating the percentage of Mrp2-associated staining within the canaliculi to total cellular staining. Mrp2, mainly confined to the canaliculi in controls, was internalized to intracellular vesicles by E17G. Apo prevented this alteration, showing a control-like distribution pattern. Apo, which inhibits migration of the cytosolic p47phox subunit of NOX, impeding the formation of the active NOX complex in the plasma membrane, prevents internalization of Mrp2 by E17G. This finding supports the location of NOX in the MEK-ERK1/2 signaling pathway, which is involved in E17G-induced internalization of canalicular transporters such as Mrp2.

138. (549) ANTICANCER EFFECTS OF GLYCOSYLATED 4-METHYLBELLIFERONE ON HEPATOCELLULAR CARCINOMA THROUGH REGULATION OF APOPTOSIS AND MIGRATION

Gisela Weiz, Alina L Gonzalez, Iara Mansilla, Javier D. Brecia, María I. Molejón

Facultad de Ciencias Exactas y Naturales, Instituto de Ciencias de la Tierra y Ambientales de La Pampa (INCITAP), Universidad Nacional de La Pampa – Consejo Nacional de Investigaciones Científicas y Técnicas (UNLPAM-CONICET), Santa Rosa, Argentina

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. We have recently reported that 4-methylumbelliferolrutinose (4MUR), an enzymatically synthesized compound, exhibit antitumoral effect on HCC. 4MUR could be used as HCC targeted therapy, without damaging non-tumoral cells or other organs. In this work we aim to understand the molecular processes involved in 4MUR-related antitumor efficacy. First, we evaluated its effect on cell death using HCC tumoral cell lines. The percentage of apoptotic Huh7 cells exposed to 4MUR significantly increased as compared with 4MU ($p < 0.001$). We next performed wound healing assays to examine the effect of the glycosylated drug on the migra-

tion of tumoral cells. 4MUR significantly inhibited the migration of Huh7 cells in a dose-dependent manner compared to the untreated group. Based on the evidence that hyaluronic acid (HA) and its receptors play an important role in tumor migration we quantified by RT-PCR the HA synthases (HAS2 and HAS3) and HA-receptor expression. In Huh7 cells, the expression of HAS2 was significantly reduced upon 4MUR treatment ($p < 0.05$), while HAS3 was not significantly affected. On the other hand, 4MUR treatment did not affect the expression of HAS2 but up-regulated HAS3 by around 3.5-fold. Whereas, no differences were obtained in CD44 expression. The results of this study revealed that 4MUR effectively induces apoptosis cell death in HCC cells. In addition, 4MUR treatment exerted anti-migration effects on HCC cells. The underlying mechanisms suggested that HCC progression was promoted via HA-dependent pathway, independently of HA-receptors inhibition. Thus, we propose that treatments interfering HA metabolism with 4-MUR may represent effective strategies for HCC treatment in the future.

139. (696) ANTIOXIDANT ACTIVITY OF ATRIAL NATRIURETIC PEPTIDE (ANP) IN THE EXOCRINE PANCREAS

Courreges, Ana P¹, Alvarez Guadalupe I¹, Ochoa Federico², Lairion Fabiana³, Zotta Elsa², Repetto Marisa³, Vatta Marcelo L^{1,4}, Bianciotti Liliana G^{1,4}.

¹Instituto de Inmunología, Genética y Metabolismo (INIGEM-UBA-CONICET), Hospital de Clínicas "José de San Martín", Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, ²Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Ciencias Biológicas, Cátedra de Fisiopatología, ³Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Ciencias Químicas, Cátedra de Química General e Inorgánica, Instituto de Bioquímica y Medicina Molecular "Profesor Alberto Boveris" (IBIMOL-UBA-CONICET), ⁴Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Ciencias Biológicas, Cátedra de Fisiología.

We previously reported that ANP is produced by the exocrine pancreas and that it plays a beneficial role in the outcome of acute pancreatitis (AP). It reduces trypsinogen activation and the inflammatory response and restores glutathione depletion. In the present study we assessed different parameters of oxidative stress and antioxidant defenses in Sprague Dawley rats with AP induced by four repetitive cerulein injections (40 μ g/Kg). Thirty minutes before the first cerulein injection animals were infused with either saline (control) or ANP (1 μ g/Kg/h) for 60 min. Following euthanasia (60 min after the last cerulein injection) pancreatic samples were harvested. ANOVA followed by a Student Newman Keuls was used for statistical analysis. Results are expressed as the mean \pm SD and $p < 0.05$ or less were considered statistically significant (*). ANP reduced NADPH oxidase activity (U/ μ g protein) (2180 \pm 256 vs. 1410 \pm 216**). As ANP increased Nrf2 nuclear translocation (0.158 \pm 0.2 vs. 0.398 \pm 0.02*) superoxide dismutase (SOD) and catalase expression were assessed by western blot and qRT-PCR. ANP increased SOD protein and mRNA expression (0.9 \pm 0.08 vs; 1.20 \pm 0.11*; 0.63 \pm 0.12 vs. 2.29 \pm 0.19*). Catalase showed no protein or mRNA changes as expected. Carbonyl content was decreased by ANP (5.60 \pm 0.6 vs. 3.60 \pm 0.9*) and TBARS showed no changes in any experimental group. The oxidized form of coenzyme Q9 (isoform in rodents) was also reduced by ANP (477.9 \pm 56.9 vs. 254.7 \pm 86.4*). These results further support previous findings showing that ANP enhances the antioxidant capacity of the pancreas in AP. Current evidence suggests that targeting only oxidative stress would not be sufficient to stop the progression of AP, a pathology characterized by a sudden onset and an unpredictably clinical course. In this sense ANP, which it is produced in the exocrine pancreas, would be beneficial since it not only improves the redox status of the pancreas but also significantly reduces premature trypsinogen activation and the local inflammatory response

140. (744) LIPOTOXIC EFFECT OF CAFETERIA DIET AND 3-METHYLCHOLANTRENE ON THE LIVER OF RATS

Marina Labiano¹, Jeremías Pablo Flores-Quiroga¹, Florencia Heinecke¹, María Agustina Meneghini¹, Alicia Graciela Fale-